Werewolf Therapeutics (NASDAQ:HOWL) reported quarterly earnings of $0.08 per share which beat the analyst consensus estimate of $(0.29) by 127.59 percent. This is a 120 percent increase over losses of $(0.40) per share from the same period last year. The company reported $21.000 million in sales this quarter.